绝经后的激素治疗与异常葡萄糖耐受性妇女的动脉样硬化进展有关
Barbara V Howard1, Judith Hsia, Pamela Ouyang
1MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783, USA. Barbara.V.Howard@MedStar.net
Circulation
|July 1, 2004
概括
绝经后的激素治疗会使冠状动脉样硬化在患有异常葡萄糖耐受性的女性中恶化. 由于心血管风险增加和炎症标志物,不建议糖尿病女性使用PHT.
科学领域:
- 心血管疾病是什么心血管疾病
- 内分泌学 在内分泌学.
- 妇女健康 妇女健康
背景情况:
- 异常葡萄糖耐受性 (AGT) 会增加心血管疾病 (CVD) 的风险,特别是在绝经后的妇女中.
- 绝经后激素治疗 (PHT) 与心血管疾病风险增加有关,在糖尿病和非糖尿病女性中观察到类似的效果.
研究的目的:
- 调查PHT对患有AGT的绝经后妇女心血管疾病的影响更差的假设.
主要方法:
- 423名患有动脉样硬化的绝经后妇女,有或没有AGT,被随机分配给PHT或安慰剂,持续约2.8年.
- 冠状动脉样硬化进展通过连续血管图进行评估.
- 测量了脂质样本,炎症标志物 (C-反应蛋白,纤维素),葡萄糖,胰岛素和胰岛素耐药性 (HOMA).
主要成果:
- 在患有AGT的女性中,PHT导致了C-反应蛋白和纤维素原的更多不良变化.
- 动脉样硬化进展在患有AGT的女性中更大,并被PHT增强.
- 在患有AGT的女性中,PHT在禁食葡萄糖,胰岛素和胰岛素耐药性方面略有改善.
结论:
- 在患有AGT的绝经后妇女中,PHT会恶化冠状动脉样硬化和炎症标志物.
- 由于这些不良影响,不建议糖尿病女性使用PHT.
- 需要进一步的研究来探索PHT对AGT妇女胰岛素抵抗和血糖的潜在益处.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...


